Stiolto Respimat - (2.5 mcg/2.5 mcg per spray ; Inhalation Spray)

Generic Name	Tiotropium Bromide and Olodaterol Hydrochloride	Innovator	Boehringer Ingelheim
Dosage	2.5 mcg/2.5 mcg per spray ; Inhalation Spray	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	STIOLTO RESPIMAT is a combination of tiotropium, an anticholinergic and olodaterol, a long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events